Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 09:25 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy
NCT03640481 · Kadmon, a Sanofi Company · PHASE2 · terminated · last registry update 2024-12-12 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The sponsor has decided to prematurely terminate the study due to the challenges encountered in recruiting adolescent participants. This decision was made without any safety concerns.” | – | Registry record, Kadmon, a Sanofi Company |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ROCK2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-07-24Phase 3 first posted: Alcon Research, Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution + Netarsudil 0.02%/latanoprost 0.005% ophthalmic solution (NCT07082816)
- 2025-05-07Phase 3 first posted: University Hospital Dubrava, Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution + Placebo (NCT06960629)
- 2025-05-02Results posted on the registry: Kadmon, a Sanofi Company, Belumosudil 200 mg QD + Belumosudil 200 mg BID (NCT05305989)
- 2025-03-06Phase 3 first posted: baotai Liang, Fasudil hydrochloride and PD1 inhibitor combined with androgen deprivation therapy + Placebo combined with androgen deprivation therapy (NCT06861192)
- 2024-04-03Results posted on the registry: Aerie Pharmaceuticals, Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution (NCT05283395)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision